Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + ifosfamide + carboplatin + etoposide + dexamethasone + cytarabine + cisplatin
- Development stage
- Unknown
- Lead developer
- University of Cologne
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This investigational combination therapy, evaluated in the Pembro-CORE trial (NCT03617666), is a chemo-immunotherapy regimen for patients with first-relapsed or refractory classical Hodgkin lymphoma (r/r cHL). It integrates the anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) with standard salvage chemotherapy regimens: ICE (ifosfamide, carboplatin, and etoposide) or DHAP (dexamethasone, high-dose cytarabine, and cisplatin). The treatment protocol utilizes a PET-guided strategy, starting with pembrolizumab and ICE (P-ICE); patients who do not achieve a complete metabolic response (CMR) after two cycles switch to pembrolizumab and DHAP (P-DHAP). Developed by the University of Cologne and the German Hodgkin Study Group, the regimen aims to maximize CMR rates to potentially allow patients to bypass the toxicity of high-dose chemotherapy and autologous stem cell transplantation (ASCT).
- Other names
- Pembrolizumab plus ICEPembrolizumab plus DHAPPembrolizumab plus salvage chemotherapy
02
Targets
GR (Glucocorticoid receptor)DNA polymerase familyDNAPDCD1 (Programmed cell death protein 1 receptor)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on pembrolizumab + ifosfamide + carboplatin + etoposide + dexamethasone + cytarabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + ifosfamide + carboplatin + etoposide + dexamethasone + cytarabine + cisplatin.